These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 27006682)

  • 1. Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study.
    Farmer A; Wang X; Ganesan A; Deiss RG; Agan BK; O'Bryan TA; Akers K; Okulicz JF
    AIDS Res Ther; 2016; 13():16. PubMed ID: 27006682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks.
    Porter DP; Kulkarni R; Garner W; Miller MD; White KL
    Antivir Ther; 2017; 22(6):495-502. PubMed ID: 28091393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
    Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
    J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.
    van Lunzen J; Antinori A; Cohen CJ; Arribas JR; Wohl DA; Rieger A; Rachlis A; Bloch M; Segal-Maurer S; Garner W; Porter D; Bosse M; Piontkowsky D; Chuck SK; De-Oertel S
    AIDS; 2016 Jan; 30(2):251-9. PubMed ID: 26684822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
    AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection.
    Di Mascio M; Markowitz M; Louie M; Hurley A; Hogan C; Simon V; Follmann D; Ho DD; Perelson AS
    J Virol; 2004 Oct; 78(19):10566-73. PubMed ID: 15367623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
    Bock P; Fatti G; Grimwood A
    Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of HIV 'blips' in resource-limited settings: is it the same? analysis of the treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD).
    Kanapathipillai R; McManus H; Kamarulzaman A; Lim PL; Templeton DJ; Law M; Woolley I
    PLoS One; 2014; 9(2):e86122. PubMed ID: 24516527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
    Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
    HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy.
    Frasca K; Morrow M; Coyle RP; Coleman SS; Ellison L; Bushman LR; Kiser JJ; Zheng JH; Mawhinney S; Anderson PL; Castillo-Mancilla J
    J Antimicrob Chemother; 2019 May; 74(5):1395-1401. PubMed ID: 30668713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Day-On, Day-Off emtricitabine, tenofovir disoproxil fumarate and efavirenz single tablet regimen (DODO) as maintenance therapy in HIV-infected patients.
    Costantini A; Tontini C; Rocchi M; Martini M; Butini L
    Infez Med; 2018 Jun; 26(2):126-132. PubMed ID: 29932084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
    Pernas B; Grandal M; Pertega S; Cañizares A; Castro-Iglesias Á; Mena Á; Rodriguez-Osorio I; Tabernilla A; Pedreira JD; Poveda E
    J Antimicrob Chemother; 2016 Apr; 71(4):1051-5. PubMed ID: 26702924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels.
    Sörstedt E; Nilsson S; Blaxhult A; Gisslén M; Flamholc L; Sönnerborg A; Yilmaz A
    BMC Infect Dis; 2016 Jun; 16():305. PubMed ID: 27329293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda.
    Castelnuovo B; Kiragga A; Mubiru F; Kambugu A; Kamya M; Reynolds SJ
    J Int AIDS Soc; 2016; 19(1):20773. PubMed ID: 27319742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.